Conference Coverage

Early PCI now favored in stable CAD


 

REPORTING FROM EUROPCR 2018


Asked what she would do differently if she could do ORBITA over again, Dr. Al-Lamee didn’t hesitate: “If I were to do it again, I absolutely agree that exercise time would not be the primary endpoint I would choose.”

SCAAR

Elmir Omerovic, MD, PhD, presented an update from the long-running observational prospective Swedish national registry. The analysis included 3,460 patients who underwent PCI for stable angina with FFR and/or iFR guidance and 21,221 others whose PCI was performed based solely on coronary angiography.

Dr. Elmer Omerovic, University of Gothenburg, Sweden Bruce Jancin/MDedge News

Dr. Elmer Omerovic

At 10 years of follow-up, total mortality was an adjusted 17% less in the FFR/iFR group. Moreover, their composite rate of restenosis/stent thrombosis was reduced by 31%, added Dr. Omerovic, professor of cardiology at the University of Gothenburg, Sweden.

At the beginning of the 10-year study period, FFR/iFR was utilized in 5%-6% of PCIs for stable CAD; today that rate has climbed to 40%, according to the cardiologist.

Pages

Recommended Reading

Endovascular interventions associated with large benefits in peripheral artery disease
MDedge Cardiology
Interventionalists skeptical about public reporting of PCI
MDedge Cardiology
CABANA: AF ablation ties drug management, with an asterisk for crossovers
MDedge Cardiology
Device-related thrombus associated with ischemic events
MDedge Cardiology
Design limitations may have compromised DVT intervention trial
MDedge Cardiology
For in-stent restenosis, everolimus-eluting stents topped drug-eluting balloons
MDedge Cardiology
Sapien M3 mitral valve replacement data reported for first 10 patients
MDedge Cardiology
TAVR safe in low-risk aortic stenosis, early data indicate
MDedge Cardiology
FDA recalls HeartMate 3 LV assist device
MDedge Cardiology
Breakthrough in noninvasive assessment of multivessel CAD
MDedge Cardiology